Gals Bio Ltd

Menses, containing numerous biomarkers to women’s health, is simply being discarded. Gals Bio, developed a vaginal platform to enable women to monitor their health from home at the accuracy of a lab.

We are currently doing our post-market study with our phase 1 initial device where more than 1500 devices were tested by more than 150 users with great initial results. In parallel, we are doing clinical study that tests the menses characteristics and we are finding biomarkers within menses that indicate women's health.

We are focusing on menstruating women in the US and EU markets that are doing sports and taking vitamins and supplements to be healthy and would like to monitor and screen their health on a regular bases. Based on this we estimate that our market size potential is about 7BUSD per year. In the future we plan to screen and monitor cancer, endometriosis , STDs and other.

Menses, which is women's monthly biopsy of her internal organs traditionally is disregarded. We are changing this reality, enabling easy, clean and reliable at home collection and analysis

GalsBio is developing a new category for women health and wellbeing that leverages the vaginal cavity and secretions to monitor and screen women's health and wellbeing from home at an accuracy and details previously available only from labs. Tulipon is a vaginal disposable device that looks and used like a tampon with an applicator, BUT it functions like a menstrual cup, where it collects the vaginal secretions. It is suitable for extended periods of use (12 hours) with worry free no leaks protection. On top of that, Tulipon enables biomarkers reading within the collected liquids

Currently there are three other companies that are developing technologies to monitor biomarkers within menses: NextGen Jane, Qurasense, and LifeStory Health, non of these companies is in the market yet and are all still in R&D. These companies are using traditional hygiene devices to collect the menses (tampons and pads) this means that they are losing data while extracting it for the absorbent material and it is problematic to do at home.

Tulipon biggest advantage is the fact that it can collect big amount of menses, up to 60ml, and it does not contain any absorbing material. Hence, no data is lost and no need to extract the collected liquids. This enables us to get access to more biomarkers. Moreover, it enables us to do the next stage of doing at home analysis without sending the sample to the lab and still get very accurate results.

We plan to enter the market with our first service within 1.5 years, where used devices will be sent to the lab for analysis. We plan to partner with current blood analysis companies, and replace their current used dry blood spot kit for women to be able to send their used Tulipon device (B2B2C). The price will be determined according to the biomarkers that are analyzed. In the second stage, in 2.5 years, we plan to get to the market with at home analysis, this will we sold at around 20USD per unit.

We have two models: 1) B2B2C: work with companies that sale vitamins and supplements to identify the unique needs of women based on the menses analysis and sale each user her specific needed supplements and to monitor their effect over time.
2)B2C: online sales for women that would like to monitor their health from home.

Getting our first device to the market and conducting clinical study to research the biomarkers within the menstrual blood.

Depending on the sum invested.

The biggest challenge of this project is to find the correct biomarkers within the menses and to find the correlation to venous blood. However, we already identified a few biomarkers as a starting point.

She Entrepreneur - from MIT

2021 women entrepreneur to watch for - FLIK

We have two patents accepted and one patent pending and more in the pipe line.